32917-51-4Relevant academic research and scientific papers
SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
-
Page/Page column 73; 74, (2015/03/28)
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Synthesis and characterization of chiral benzylic ether-bridged periodic mesoporous organosilicas
Morell, Juergen,Chatterjee, Sangam,Klar, Peter J.,Mauder, Daniel,Shenderovich, Ilja,Hoffmann, Frank,Froeba, Michael
experimental part, p. 5935 - 5940 (2009/05/31)
The first synthesis of a chiral periodic mesoporous organosilica (PMO) carrying benzylic ether bridging groups is reported. By hydrolysis and condensation of the new designed chiral organosilica precursor 1,4-bis(triethoxysilyl)-2-(1 -methoxyethyl)benzene
